Health TrialsbyHealthPanel

RCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders

ConditionsPsychotic DisordersCannabis Use DisorderMental Health Disorder
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCiusss de L'Est de l'Île de Montréal

About this trial

The goal of this clinical trial is to conduct a single-blind randomized controlled trial to verify whether the Avatar Intervention has greater efficacy over supportive intervention to reduce cannabis use in patients with psychotic disorders.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Males or females over 18 years of age who meet the DSM-5 criteria for CUD (≥4 criteria) ;

Patients will meet the DSM-5 criteria for schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic symptoms. Diagnoses will be established with the Structured Interview for DSM-5 (SCID-5).

Disqualifiers

Current SUD for a substance other than cannabis ;

Ongoing pharmacological or psychological treatment for CUD ;

Ongoing detoxification for cannabis withdrawal ;

Presence of neurological disorders ;

Trial design

Design model

Crossover

Treatments tested in this trial

  • Avatar Intervention

    Other intervention

    8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.

  • Addiction supportive intervention

    Other intervention

    8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.

Treatment groups

150 Participants
are divided into 2 treatment groups
Group A: Avatar InterventionExperimental treatment 1 intervention
Group B: Addiction supportive interventionActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in cannabis use (Timeline Follow-Back)

A standardized tool consisting of asking the patients how many joints they smoked each day of the week during the past week.

Time frame
Within 1 week before treatment, within 1 week after treatment, follow-ups at 3 months, 6 months and 12 months

Secondary outcomes

1

Change in the severity of the cannabis use disorder (Cannabis Use Problems Identification Test - CUPIT)

16-item self-reported questionnaire assessing cannabis use and dependence; Range 3-82, higher values indicating a more severe cannabis use disorder

Time frame
Within 1 week before treatment, within 1 week after treatment, follow-ups at 3 months, 6 months and 12 months
2

Change in quality of life(Quality of Life Enjoyment and Satisfaction Questionnaire - QLESQ-SF & Quality of Life Scale - QLS)

QLESQ-SF: 16-item self-reported scale measuring enjoyment and satisfaction experienced during the past week in various areas of daily functioning; Range 14-70, Higher values indicate a better satisfaction of life QLS: 21-item scale based on a semistructured interview designed to assess deficit symptoms; Range 0-126, higher values indicate a better quality of life

Time frame
Within 1 week before treatment, within 1 week after treatment, follow-ups at 3 months, 6 months and 12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Ciusss de L'Est de l'Île de Montréal

Lead sponsor

Canadian Institutes of Health Research (CIHR)

Collaborator

Source ClinicalTrials.gov
Apply now